贝达药业涨2.06%，成交额2.47亿元，主力资金净流出2627.22万元

Group 1 - The core viewpoint of the news is that 贝达药业 (Bida Pharmaceutical) has shown fluctuations in stock performance and financial metrics, indicating both growth and challenges in its operations [1][2] Group 2 - As of August 25, 贝达药业's stock price increased by 2.06% to 66.38 CNY per share, with a total market capitalization of 27.93 billion CNY [1] - The company has experienced a year-to-date stock price increase of 23.54%, but a recent decline of 3.80% over the last five trading days [1] - The main business revenue composition is 99.10% from drug sales and 0.90% from other sources [1] Group 3 - For the first half of 2025, 贝达药业 reported a revenue of 1.73 billion CNY, reflecting a year-on-year growth of 15.37%, while the net profit attributable to shareholders decreased by 37.53% to 140 million CNY [2] - The number of shareholders increased by 9.97% to 32,100, while the average circulating shares per person decreased by 9.08% to 13,064 shares [2] Group 4 - The company has distributed a total of 669 million CNY in dividends since its A-share listing, with 184 million CNY distributed over the past three years [2] - Notable institutional holdings include 易方达创业板ETF (E Fund ChiNext ETF) as the fifth largest shareholder, holding 6.37 million shares, a decrease of 107,600 shares from the previous period [2]